Our Amgen medical directors in oncology can take kyprolis from here.
Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma
HOUSAND OAKS, Calif., May 31, 2015 /PRNewswire/ -- Amgen AMGN, -0.69% today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). The trial was initiated based on results from the Phase 1/2 CHAMPION study, which were presented (abstract no. 8527) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday, May 31 at 8 a.m. CT.
Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma
HOUSAND OAKS, Calif., May 31, 2015 /PRNewswire/ -- Amgen AMGN, -0.69% today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). The trial was initiated based on results from the Phase 1/2 CHAMPION study, which were presented (abstract no. 8527) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday, May 31 at 8 a.m. CT.
Onyx - no need for your clinical folks from here on out
Aucun commentaire:
Enregistrer un commentaire